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A B S T R A C T
The combined use of opioid and benzodiazepine medications increases the risk of hazardous effects, such as
respiratory depression. Although recent increases in outpatient use of opioid prescriptions have been docu-
mented, there are limited data regarding rates and correlates of combined opioid and benzodiazepines among
adults in outpatient settings. Our objective was to examine annual trends in outpatient visits including opioids,
benzodiazepines, and their combination among adults as well as clinical and demographic correlates. We used
data from the 1993–2014 National Ambulatory Medical Care Survey (NAMCS) among non-elderly (i.e., ages
18–64 years) adults to examine the probability of a visit including an opioid, benzodiazepine, or their combi-
nation, in addition to clinical and demographic correlates. From 1993 to 2014, benzodiazepines-with-opioids
visits increased from 9.8 to 62.5 (OR = 9.23, 95% CI = 5.45–15.65) per 10,000 visits. Highest-represented
groups among benzodiazepines-with-opioids visits were older (50–64 years) (49.1%), white (88.8%), commer-
cially insured (58.0%) patients during their first visit (87.6%) to a primary-care physician (41.9%). We identified
a significant increase in the outpatient co-prescription of opioids and benzodiazepines, notably among adults
aged 50–64 years during primary-care visits. Educational and policy changes to provide alternatives to benzo-
diazepine-with-opioid co-prescription and limiting opioid prescription to pain specialists may reduce rates of this
potentially hazardous combination.
1. Introduction
In the period between 1993 and 2014, the number of opioid an-
algesic prescriptions dispensed from retail pharmacies in the United
States (US) increased from roughly 113 million to 264 million (Pezalla
et al., 2017), with a corresponding increase in opioid-related diversion,
abuse, and deaths between 2002 and 2010 (Dart et al., 2015). Similarly,
between 1996 and 2013, the percentage of US adults who filled a
prescription for a benzodiazepine increased from 4.1% to 5.6%, during
which time the rate of deaths attributed to benzodiazepine overdoses
increased from 0.58 to 3.07 per 100,000 adults (Bachhuber et al.,
2016).
Although rates of outpatient prescription of opioids (Dart et al.,
2015) and benzodiazepines (Bachhuber et al., 2016) may be stabilizing
or decreasing in the years since 2010, the overall rates remain greatly
elevated compared to previous decades. In addition, among adults who
are prescribed opioids for daily use, nearly 40% have a concurrent
prescription for a benzodiazepine. This is especially concerning given
the increased risk of respiratory depression, overdose, and death asso-
ciated with the co-administration of these two classes of medications
(Karaca-Mandic et al., 2017; Saunders et al., 2012; Jann et al., 2014).
For instance, in a prospective, outpatient-based study of adult patients
prescribed high-dose opioids, those concurrently prescribed benzodia-
zepines were nearly 10 times more likely to die from overdose
(Dasgupta et al., 2016). Similarly, among adults in the Veterans Health
Administration who received prescriptions for opioids, nearly half of
drug overdose deaths occurred among those concurrently prescribed
benzodiazepines (Park et al., 2015). Privately insured, nonelderly
adults who received prescriptions for both opioids and benzodiaze-
pines, compared to opioids alone, were more likely to visit the emer-
gency department or have an inpatient admission for opioid overdose
(Sun et al., 2017). Furthermore, in the emergency department setting
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between 2004 and 2011, the percentage of opioid overdose deaths
among adults that also involved benzodiazepine use increased steadily
from 18% to 31% (Jones and McAninch, 2015).
In light of these and similar data, the Centers for Disease Control
and Prevention (CDC) released revised guidelines (Dowell et al., 2016)
for prescribing opioid analgesics for chronic pain in 2016, which re-
commend that “clinicians should avoid prescribing opioid pain medi-
cation and benzodiazepines concurrently whenever possible.” However,
despite the well-documented risk of death from concurrent adminis-
tration of opioids and benzodiazepines, less is known about the trends
in general, outpatient prescribing patterns of these two classes of
medications. Recent analyses of US prescription claims has revealed
increased rates of co-prescription of benzodiazepines and opioids
among non-elderly adults (Hwang et al., 2016) and adults receiving
opioids for musculoskeletal pain (Larochelle et al., 2015). However,
these studies have generally limited analyses to the years subsequent to
2001; this excludes the 1990s, which was also marked by a steady in-
crease in rates of opioid prescriptions. In addition, previous studies
have either used administrative or claims-level data (Sun et al., 2017;
Hwang et al., 2016), which may be associated with validity issues
(Strom, 2001), or focused on specific populations of adults (Larochelle
et al., 2015).
Therefore, to address this gap in the literature, we sought to ex-
amine trends in the outpatient administration of opioids, benzodiaze-
pines, and their combination among nonelderly adults from 1993 to
2014, clinical and demographic correlates of prescription patterns, and
likelihood of physicians co-prescribing opioids and benzodiazepines. To
achieve these aims, we used prospectively collected, nationally re-
presentative data from the National Ambulatory Medical Care Survey
(NAMCS). We anticipate that results from these analyses will inform
clinical and policy decisions by specifically identifying adults and
clinicians who are at highest risk for benzodiazepine and opioid coad-
ministration.
2. Material and methods
2.1. Sample
We used data from the 1993–2014 NAMCS, an annual, cross-sec-
tional, nationally representative probability sample survey of non-fed-
erally employed office-based physicians, administrated by National
Center for Health Statistics (NCHS) of the Centers for Disease Control
and Prevention (National Center for Health Statistics, 2017). We limited
our analysis to visits by patients aged 18–64 years (n= 402,027).
Physicians specializing in anesthesiology, pathology, and radiology are
excluded from the survey, as well as home-based visits or those within
institutional settings (e.g., nursing homes). Survey response rates varied
from 38.7% in 2014 to 73.1% in 1993 (mean = 61.6%). Within each
patient visit, either the physician or a staff member recorded informa-
tion about patient characteristics and medications that were “ordered,
supplied, administered, and continued.” Detailed information regarding
NAMCS administration and coding can be accessed elsewhere (Centers
for Disease Control and Prevention, 2017). Because this research in-
volves use of de-identified data, it was exempt from review by the In-
stitutional Review Board of the University of California, San Francisco.
2.2. Medications
During the years 1993 to 2014, NAMCS forms allowed extraction of
five to 30 current medications; to maintain consistency across years, we
limited our analyses to the first five medications listed. Starting in
2006, NAMCS medications were coded using Lexicon Plus®, a pro-
prietary database of Cerner Multum, Inc.; medication data from survey
years prior to 2006 were recoded into Lexicon Plus® therapeutic classes
using syntax developed by the NCHS. Visits were considered benzo-
diazepine visits if they were included in the Therapeutic Category Level
3, “069 – benzodiazepines” (i.e., alprazolam, chlordiazepoxide, clona-
zepam, clorazepate, diazepam, estazolam, flurazepam, halazepam,
lorazepam, midazolam, nitrazepam, oxazepam, prazepam, quazepam,
temazepam, or triazolam). Visits were considered opioid visits if they
were included in the Therapeutic Category Level 3, “060 – analgesics”
(i.e., alphaprodine, codeine, dezocine, diphenoxylate, fentanyl, glu-
tethimide, hydrocodone, hydromorphone, levorphanol, meperidine,
methadone, morphine, nalbuphine, opium, oxycodone, oxymorphone,
pentazocine, propoxyphene, remifentanil, sufentanil, or tapentadolor).
2.3. Demographic characteristics
We classified visits by patient sex, age at time of visit (18–34,
35–49, or 50–64 years), and race (white, black, or other). Because
ethnicity was not recorded consistently among the included survey
years, this variable was excluded from our analyses.
2.4. Primary source of payment
Following guidelines established by the NCHS, we grouped visits
into mutually exclusive payment categories in descending order:
(Pezalla et al., 2017) private-pay or commercial, (Dart et al., 2015)
Medicare, (Bachhuber et al., 2016) Medicaid and other government
insurance (including the Children's Health Insurance Program), or
(Karaca-Mandic et al., 2017) other (self-pay, no charge, or “other”).
2.5. Reasons for visit and diagnoses
Survey forms included up to three patient-generated reasons-for-
visit (RFV) as well as up to three visit diagnoses (using the International
Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-
CM]). Pain was classified based on physical location into six categories
using RFVs: head or neck, chest, abdomen or pelvis, back or hip, ex-
tremities, or unspecified. We also identified visits in which any pain was
listed as the primary (i.e., first listed) RFV. Visits were also classified by
relevant diagnoses based on ICD-9-CM codes: low-back pain (722.10,
722.52, 724.2–724.6, 738.4, 756.11, 839.2, 846.0, 847.2), cancer
(140–239, 338.3), anxiety disorders (293.84, 300.0, 300.2–300.3,
308.3, 309.21, 309.81, 313.0), substance use disorders (291–292,
303–305), depressive disorders (296.2, 296.3, 300.4, 311), and in-
somnia (307.4, 327.00, 327.01, 327.02, 327.09, 780.50, 780.51,
780.52, 780.55, 780.56, 780.59).
2.6. Other visit-level characteristics
We grouped visit status as a first or returning visit by whether the
treating physician or anyone in the practice had seen the patient before.
In addition, we recoded the specialty of the treating physician as pri-
mary care (internal medicine, geriatric medicine, adolescent medicine,
pediatrics, family practice, and general practice), psychiatry, or another
medical specialty.
2.7. Statistical analysis
We used logistic regression to assess year-by-year time trends in the
probability of that visits included any 1 of the 3 medication groups,
controlling for patient age and race. We assigned a study-year period
variable ([survey year-1993]/22) to examine the strength of association
of medication-group prescription from 1993 through 2014. The re-
sultant odds ratios for each medication group estimates the change in
odds of a visit containing the medication group relative to a visit in
which neither benzodiazepines nor opioids were prescribed over the
entire 1993–2014 study period. We compared differences in proportion
by visit characteristics using χ2 tests. Among visits with physician-level
weights (2005–2014, n= 6338), we similarly used logistic regression
to examine time trends of the 3 medication groups controlling for the
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visits per physician. Analyses were adjusted for visit weights, clustering,
and strata using complex survey-design elements; incorporating these
elements yields data that are reflective of annual visits to US office-
based physicians. We performed analyses using SAS, version 9.4 (SAS
Institute), with 2-sided tests (α= 0.05).
3. Results
Fig. 1 illustrates the year-by-year frequency with which benzodia-
zepines-with-opioids visits occurred over the study period for the entire
sample. Between 1993 and 2014, annual benzodiazepines-with-opioids
visits increased from 9.8 to 62.5 (OR = 9.23, 95% CI = 5.45–15.65)
per 10,000 visits, benzodiazepines-only visits from 288.3 to 682.4 per
10,000 visits (OR = 8.18, 95% CI = 4.12, 16.25), and opioids-only
visits from 15.4 to 247.2 per 10,000 visits (OR = 5.63, 95%
CI = 3.17–10.02). Between 2005 and 2014, an increased proportion of
physicians provided benzodiazepines-with-opioids visits (0% in 2005 to
1.41% in 2014; OR = 47.56, 95% CI = 6.95, 325.46), but not benzo-
diazepines-only (1.61% in 2005 to 10.49% in 2014; OR = 1.09, 95%
CI = 0.66, 1.79) or opioids-only visits (0.75% in 2005 to 4.03% in
2014; OR = 2.16, 95% CI = 0.82, 5.72).
In contrast to Fig. 1, Table 1 uses combined data from all 22 survey
years to examine visit characteristics associated with each of the 3
medication groups. Nearly 42% of benzodiazepines-with-opioids visits
were among primary care physicians, compared with 2.9% among
psychiatrists and 55.2% among other medical specialties. Furthermore,
benzodiazepines-with-opioids visits were concentrated among older
(50–64 years, 49.1%), white (88.8%), commercially insured (58.0%)
adults with a low-back pain diagnosis (19.7%) during their initial visit
to the index physician (87.6%). Notably, the distribution of payer types
differed significantly between opioids-only and (p < 0.001), with
more commercially insured benzodiazepines-only visits compared with
opioid-only visits. Compared to benzodiazepines-with-opioids visits,
benzodiazepines-only visits (p < 0.0001), but not opioids-only visits,
were significantly more likely to be by men than women. In regards to
the type of pain, benzodiazepines-with-opioids visits were more likely
than opioids-only visits for back/hip pain (p < 0.001); however,
benzodiazepines-with-opioids visits and opioids-only visits occurred at
similar rates for pain of the head/neck, chest, abdominal/pelvic, ex-
tremities, and for unspecified locations. Furthermore, a diagnosis of a
substance use disorder occurred among a significantly higher percen-
tage of benzodiazepines-with-opioids visits than among opioids-only
visits (p < 0.001), but not among opioids-only visits. Among benzo-
diazepines-with-opioids visits, low-back pain represented the largest
diagnostic category (19.7%).
4. Discussion
Between 1993 and 2014, the proportion of outpatient medical visits
that included co-prescription of benzodiazepines with opioids more
than doubled. The increase more closely followed the prescription of
benzodiazepines without opioids than with prescription of opioids
alone. Notably, a substantial percentage of these visits were in primary-
care settings and occurred during the initial visit, suggesting a need to
reduce the inappropriate use of opioids in non-specialist settings. Our
finding that low-back pain represented the single highest diagnostic
correlate of co-prescription of benzodiazepines and opioids is especially
concerning given limited evidence supporting the use of opioids for
low-back pain (Abdel Shaheed et al., 2016). Furthermore, the fact that
substance use disorders were more frequently observed among benzo-
diazepines-with-opioids compared with opioids-only visits is alarming
given the abuse additive abuse potential of these 2 sedative medications
compared with either alone.
These results, in particular increased rates of visits with both ben-
zodiazepines and opioids, are particularly relevant in the context of
increased rates of drug overdose deaths in the past 2 decades. For in-
stance, Rudd et al., using data from the National Vital Statistics System
multiple cause-of-death mortality files, demonstrated that the number
of drug overdose deaths among adults in the US tripled between 2000
and 2014 (Rudd et al., 2016a); in the period from 2014 to 2015 alone,
Fig. 1. Trends in annual ambulatory prescribing of Schedule IV benzodiazepines, Schedule II opioids, or both, United States.
Number of annual visits among each medication group, 1993–2014; all analyses were conducted using survey-design elements for visit or physician weight, clustering, and stratification
to yield national inferences.
M.E. Hirschtritt et al. Preventive Medicine Reports 9 (2018) 49–54
51
the number of drug-overdose deaths associated with synthetic opioids
other than methadone increased by 72.2% from 1.8 to 3.1 per 100,000
population (Rudd et al., 2016b). Concurrent benzodiazepine use has
also contributed to the increased rate of opioid-related overdose deaths.
For instance, Kandel et al., also using National Vital Statistics System
data, demonstrated that the proportion prescription opioid-related
deaths attributable to combined use with benzodiazepines increased 1.7
times from 16.8% to 27.9% between 2002–2003 and 2014–2015
(Kandel et al., 2017). Similarly, nationally representative data from US
emergency departments reveals that drug overdose deaths involving
both opioids and benzodiazepines increased nearly three-fold in the
period from 2004 to 2011 from 0.6 to 1.7 per 100,000 population;
furthermore, benzodiazepine involvement in opioid-related overdose
deaths increased from 18% to 31% in the same 7-year period (Jones and
McAninch, 2015). Taken together, these results further support the
importance of quantifying co-prescription of opioids and benzodiaze-
pines, as this practice may be contributing to combined opioid-benzo-
diazepine overdose deaths in the US.
These results should also be considered in the context of a related
trend; namely, in the period between 1999 and 2013, the annual all-
cause mortality of middle-aged (ages 45–54 years), white, non-Hispanic
US adults increased by 33.9 per 100,000 population (Case and Deaton,
2015). Primary causes of these deaths included poisonings and suicides;
furthermore, increased mortality in this subpopulation paralleled in-
creases in morbidity, including worsened self-reported mental and
physical health, daily functioning, and increased alcohol use. This trend
contrasts with decreased morbidity over the same period among most
other demographic groups. Increased mortality due to these “diseases of
Table 1
Volume and distribution of annual ambulatory medical visits including Schedule IV benzodiazepines, Schedule II opioids, or both by background patient demographic and clinical
characteristics, United States, 1993–2014.
Visits, % Comparisons a
1. Both opioids and
benzodiazepines
(N= 1350)
2. Opioids, no benzodiazepines
(N= 5351)
3. Benzodiazepines, no opioids
(N= 19,413)
Sexb
Male 45.1 46.3 34.3 1—3⁎⁎⁎, 2—3⁎⁎⁎
Female 54.9 53.7 65.7
Ageb
18–34 15.6 16.2 17.8 1—3⁎, 2—1⁎
35–49 35.3 41.5 39.4
50–64 49.1 42.4 42.8
Raceb
White 88.8 85.3 89.5 1—2⁎, 2—3⁎⁎⁎
Black 7.4 11.5 7.9
Other 3.8 3.1 2.6
Primary payerb
Commercial 58.0 54.9 61.6 2—3⁎⁎⁎
Medicare 14.2 15.0 13.0
Medicaid 11.7 14.2 10.2
Self-pay or other 16.1 15.9 15.6
Visit statusb
First visit 87.6 88.6 91.0 2—3⁎⁎
Return visit 12.4 11.4 9.0
Pain as reason for first visitc 27.7 37.3 13.7 3 < 2⁎⁎⁎, 2 > 1⁎⁎, 3 < 1⁎⁎⁎
Type of painc
Head/neck 7.7 9.6 5.0 3 < 2⁎⁎⁎, 3 < 1⁎
Chest 1.5 1.5 1.7 NS
Abdominal/pelvic 3.8 3.5 2.5 3 < 2⁎⁎, 3 < 1⁎
Back/hip 13.9 21.8 6.1 3 < 2⁎⁎⁎, 2 > 1⁎⁎⁎,
3 < 1⁎⁎⁎
Extremities 10.3 13.4 5.1 3 < 2⁎⁎⁎, 3 < 1⁎⁎⁎
Unspecified 8.8 8.4 2.4 3 < 2⁎⁎⁎, 3 < 1⁎⁎⁎
Physician specialtyb
Primary care 41.9 47.8 49.0 2—3⁎⁎⁎, 1—3⁎⁎⁎
Psychiatry 2.9 4.6 27.0
Other 55.2 47.6 24.0
Selected medical or mental health
problemc
Low-back pain 19.7 15.9 5.7 3 < 2⁎⁎⁎, 3 < 1⁎⁎⁎
Cancer 5.5 8.2 2.8 3 < 2⁎⁎⁎, 2 > 1⁎, 3 < 1⁎⁎⁎
Anxiety 1.2 7.4 25.8 3 > 2⁎⁎⁎, 2 > 1⁎⁎⁎,
3 > 1⁎⁎⁎
Substance use 6.4 2.1 3.7 2 < 1⁎
Depression 3.5 6.2 21.2 3 > 2⁎⁎⁎, 2 > 1⁎, 3 > 1⁎⁎⁎
Insomnia 1.0 1.5 3.2 3 > 2⁎⁎⁎, 3 > 1⁎
Analyses were conducted using survey-design elements for visit weight, clustering, and stratification to yield national inferences.
a Difference-in-ratio (chi-squared) tests among the 3 medication groups; directionality for significant between-group differences is indicated only for 1 × 3 tables. NS, not significant.
b Percentages represent the fraction of the listed categories (e.g., 34.3% of total visits in which benzodiazepines, but no opioids, were prescribed were among males and the remainder,
65.7%, were among females). Values within columns may not sum to 100% because of rounding.
c Percentages represent the fraction of visits within each item (e.g., 5.7% of total visits in which benzodiazepines, but no opioids, were prescribed included a diagnosis of lower-back
pain and the remainder, 94.3%, did not).
⁎ P < 0.05.
⁎⁎ P < 0.01.
⁎⁎⁎ P < 0.001.
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despair” (Kochanek et al., 2016) among middle-aged, white adults is
especially pertinent in light of our findings, given the potential use of
combined opioids and benzodiazepines in intentional overdose deaths,
as well as our finding that white adults were more likely than other
racial groups to receive combined opioids and benzodiazepines over the
study period.
Taken together, the results of the current study suggest that limiting
the prescription of benzodiazepines may slow the increased co-pre-
scription of benzodiazepines with opioids and seeking to confine co-
prescription to specialists trained in pain management. This re-
commendation is hindered, however, by a shortage of pain specialists in
the US; in its 2011 report on pain management, the Institute of
Medicine estimated that there was only one pain specialist per 28,500
individuals with pain (Institute of Medicine of the National Academies,
2011). When a pain specialist is not available, alternatives to benzo-
diazepines should be considered for patients with pain and anxiety
including selective-serotonin reuptake inhibitors and cognitive-beha-
vioral therapy, as well as alternative interventions such as acupuncture
and physical therapy (Rosenberg et al., 2008). Likewise, non-opioid
analgesic treatments should be considered, including behavioral ap-
proaches (e.g., cognitive-behavioral therapy), acupuncture, physical
therapy, and non-opioid medications such as nonsteroidal antiin-
flammatory drugs (Dowell et al., 2016).
There are several limitations of this study. First, the variable non-
response rate among survey years introduces a potential source of bias.
Second, we are not able to determine whether the visit physician pre-
scribed the listed medications for those listed as “continued;” for in-
stance, an opioid may have been prescribed by other physician prior to
the recorded encounter. Third, NACMS does not contain information
regarding medication adherence, strength, duration of treatment, or
whether the medication is taken on a scheduled or as-needed basis.
Fourth, because only up to three RVFs and visit diagnoses were al-
lowed, the RVF or diagnosis associated with a given medication may
have been missing from a visit. Fifth, because NAMCS is limited to
office-based visits, it does not capture visits to emergency departments,
hospital outpatient clinics, cancer centers, and other outpatient medical
settings where opioids and benzodiazepines are prescribed. Similarly,
sixth, for the same reason, NAMCS does not capture non-medical use of
opioids and benzodiazepines (e.g., use of others' prescribed medica-
tions, or receipt from non-medical providers in the community).
As a final consideration, many patients with opioid use disorder
receive pharmacologic treatment with either methadone (a full opioid
agonist) or buprenorphine (a partial opioid agonist). Increasingly, pa-
tients are alternatively offered buprenorphine-naloxone (to reduce
abuse potential) or naltrexone (an opioid antagonist). These patients
may concurrently use benzodiazepines, which may be as hazardous as
the combination of non-methadone opioids and benzodiazepines.
Concurrent use of benzodiazepines and methadone has been implicated
in methadone-related deaths (Chan et al., 2006; Mikolaenko et al.,
2002), likely because benzodiazepines compete for opioid receptors and
may inhibit hepatic enzymes responsible for degrading methadone.
Furthermore, among patients engaged in methadone maintenance
therapy, concurrent benzodiazepine use has been associated with
higher rates of opioid-positive urine samples during treatment (Brands
et al., 2008). However, although there may be less risk of fatal overdose
when benzodiazepines are taken in combination with buprenorphine
(instead of methadone) (Nielsen et al., 2007), concurrent benzodiaze-
pine and buprenorphine users are still at higher risk of more frequent
emergency department visits for accidental injury (Schuman-Olivier
et al., 2013) and higher rates of depression and anxiety (Lavie et al.,
2009).
Given our focus on combined benzodiazepine and prescription
opioids in this study, as well as the consideration that buprenorphine
may not be accurately represented in the NAMCS data because they are
primarily prescribed in chemical-dependency treatment facilities, we
did not examine visits with methadone or buprenorphine specifically.
However, given the widespread use of these medications in pain man-
agement and opioid use disorder treatment, trends in use of these
medications in combination with benzodiazepines should be pursued in
future studies, especially using data that incorporate chemical-de-
pendency treatment centers.
4.1. Implications
Among the 47 studies included in a recent systematic review of
causes of increased opioid-related mortality in the United States and
Canada between 1990 and 2013, 14 included polydrug toxicity as a
major factor (King et al., 2014). In addition, public-health research on
the causes of the opioid epidemic has shifted from focus on misuse and
diversion of prescription analgesics to iatrogenic addiction (Beauchamp
et al., 2014), attributable to the increased prescription of opioids for
various indications. In this context, the observed increased rate of visits
containing both opioids and benzodiazepines calls for public health
action.
Educational initiatives may help to stem the increase in opioid and
benzodiazepine co-prescriptions. For instance, the Surgeon General, as
part of the “Turn the Tide” campaign, distributed a two-page pocket
guide (The Office of the Surgeon General, n.d.) for reducing use of
opioids for chronic pain and summarizes the CDC guidelines (Dowell
et al., 2016) in an easy-to-access format. Though this guide suggests
prescribers monitor for concomitant benzodiazepine use, more directed
efforts may be made to explicitly list the clinical hazards of opioid and
benzodiazepine co-prescription, and provide safe alternatives in spe-
cific clinical scenarios. Other strategies to address this public health
issue include simultaneous policy initiatives, such as increased support
for and mandated use of prescription-drug monitoring programs
(Gugelmann and Perrone, 2011), regulating so-called opioid pill-mill
pain clinics, and establishing dosage thresholds (Garcia, 2013).
Furthermore, clinicians should remain vigilant for sleep disordered
breathing associated with opioids and benzodiazepines, especially
when used together. Among patients with chronic opioid therapy
(i.e., > 90 days), as many as 85% may have central, obstructive or
mixed-type sleep apnea, as verified by polysomnography (Mogri et al.,
2009). In addition, higher chronic benzodiazepine doses are associated
with greater incidence of central sleep apnea among patients with
chronic opioid therapy (Hassamal et al., 2016). Therefore, physicians
treating patients with chronic opioid therapy and concomitant benzo-
diazepines should consider referral for home- or laboratory-based
polysomnography, especially in the presence of other risk factors for
obstructive sleep apnea (e.g., elevated body-mass index, thick neck
circumference, smoking, male sex) and central sleep apnea (e.g., history
of stroke, cardiovascular disease) (Cheatle and Webster, 2015). Other
risk-mitigation strategies include reduction of opioid dose, substitution
of opioids with non-opioid analgesics, avoidance of polypharmacy with
other sedative medications (e.g., benzodiazepines, hypnotics), reduc-
tion or elimination of concurrent alcohol use, and referral to a sleep-
medicine specialist (Cheatle and Webster, 2015).
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